Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Illumina (ILMN)
Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Illumina today. The company’s shares closed last Friday at $133.12.
According to TipRanks.com, Ryskin is a 1-star analyst with an average return of
Currently, the analyst consensus on Illumina is a Hold with an average price target of $144.90, implying an 8.8% upside from current levels. In a report released today, Barclays also assigned a Sell rating to the stock with a price target.
See Insiders’ Hot Stocks on TipRanks >>
Moderna (MRNA)
In a report released today, Joseph Stringer from Needham maintained a Hold rating on Moderna, with a price target of $45.94. The company’s shares closed last Friday at $46.10, close to its 52-week low of $29.25.
According to TipRanks.com, Stringer is a 5-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $38.23, representing a -18.0% downside. In a report issued on April 21, Bernstein also maintained a Hold rating on the stock with a $45.00 price target.
Dexcom (DXCM)
In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Dexcom. The company’s shares closed last Friday at $61.57.
According to TipRanks.com, Steed is a 2-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $81.58, which is a 33.8% upside from current levels. In a report issued on April 16, TipRanks – xAI also upgraded the stock to Buy with a $72.00 price target.
Read More on ILMN:
